Laser vs Bleomycin for infant hemangioma in babies
Part of Skin clinical trials.
This study compares using a diode laser versus a medicine called bleomycin to treat infantile hemangiomas (red birthmarks) in babies. The goal is to see which treatment works better and is safer for young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 months and 1 year old.
- The hemangioma should be uncomplicated (not bleeding, ulcerated, or affecting vital functions).
- The diagnosis must be infantile hemangioma (not other types of birthmarks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a lower dose of the drug bleomycin works as well in electrochemotherapy for skin or under-the-skin tumors. The goal is to reduce side effects while still treating cancer effectively.
This study compares three approaches—pulsed-dye laser, timolol (a medicated skin solution), or watch-and-wait—to see which works best to slow the growth of a hemangioma birthmark in young babies. It may help find a treatment that shrinks or controls the birthmark as early as possible.
This trial tests a medicine called bleomycin, injected into lymphatic malformations (abnormal fluid-filled growths) to shrink them. It is for children under 14 whose malformations are growing quickly, causing symptoms or problems, and cannot be removed by surgery alone.
This trial tests a treatment called bleomycin electrosclerotherapy (BEST) for low-flow vascular malformations—abnormal blood vessel or lymph vessel growths that haven't responded well to previous treatments. The treatment involves injecting bleomycin (a medication) directly into the malformation and using electrical current to help destroy it.
This trial tests two different injections (bleomycin vs doxycycline) to see which works better for shrinking large or mixed lymphatic malformations in children. It's a first treatment option for young children who haven't had any prior therapy.
This study looks at babies with a type of birthmark called infantile hemangioma (including those that barely grow or have stopped growing). Researchers want to understand the risks and decide on the best treatment.
Hear when a new Bleomycin Adverse Reaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.